Addition of Spironolactone to Ambrisentan May Be a Novel Treatment Strategy to Improve Outcome in Patients with PAH

Article Information

DOI 
http://dx.doi.org/10.1177/155989771304007
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2013 MD Conference Express®

Author Information

  1. Maria Vinall
  1. Bradley Maron, MD
    1. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
View Full Text

Article usage

AbstractFullPDF
Apr 20151100
Jun 2015200
Jul 2015100
Aug 2015111
Oct 2015532
Total2043

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Addition of Spironolactone to Ambrisentan May Be a Novel Treatment Strategy to Improve Outcome in Patients with PAH
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Thromboembolic Disease
Pulmonary Clinical Trials
Pulmonary & Critical Care
Thromboembolic Disease
Pulmonary Clinical Trials
Pulmonary & Critical Care